MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu-Wong, J. R.
Right arrow Articles by Opgenorth, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu-Wong, J. R.
Right arrow Articles by Opgenorth, T. J.

Phosphoramidon modulates the number of endothelin receptors in cultured Swiss 3T3 fibroblasts

JR Wu-Wong, WJ Chiou and TJ Opgenorth

Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064.

Endothelin (ET) is generated from prepro-ET by dibasic pair proteolysis, followed by specific proteolytic cleavage between Trp21 and Val22. Currently, intense research efforts are focused on the investigation of a metalloprotease-like ET-converting enzyme that is inhibited by phosphoramidon but not by other inhibitors of neutral metalloproteases. In this report, we show that ET binding was increased significantly in cultured Swiss 3T3 fibroblasts after phosphoramidon treatment. Saturation studies using membranes prepared from cells or using intact cells assayed at 4 degrees showed that Bmax increased from 0.13 pmol/mg or 0.038 pmol/1 x 10(6) cells in untreated cells to 0.66 pmol/mg or 0.22 pmol/1 x 10(6) cells in cells treated with 100 microM phosphoramidon for 24 hr, equivalent to a net increase of 100,000 ET binding sites/cell. The effect of phosphoramidon was time and dose dependent. Other protease inhibitors, such as thiorphan, pepstatin A, E- 64, phenylmethylsulfonyl fluoride, bestatin, and leupeptin, failed to exert a similar effect. Reverse phase high performance liquid chromatography analysis indicated that the effect of phosphoramidon was not due to inhibition of 125I-ET-1 degradation. The effect of phosphoramidon remained evident after cells were treated with actinomycin D or cycloheximide to inhibit protein synthesis, suggesting that the phenomenon was not due to the effect of phosphoramidon stimulating the synthesis of ET receptors. Degradation studies suggested that the effect of phosphoramidon was due to inhibition of a protease responsible for degrading the ET receptor. The fact that Swiss 3T3 cells treated with phosphoramidon exhibit an increase in the number of ET receptors is likely to complicate the interpretation of results when phosphoramidon or related compounds are used to block the putative ET-converting enzyme.

Volume 44, Issue 2, pp. 422-429, 08/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Circ. Res.Home page
E. Suzuki, D. Nagata, M. Kakoki, H. Hayakawa, A. Goto, M. Omata, and Y. Hirata
Molecular Mechanisms of Endothelin-1–Induced Cell-Cycle Progression : Involvement of Extracellular Signal-Regulated Kinase, Protein Kinase C, and Phosphatidylinositol 3-Kinase at Distinct Points
Circ. Res., March 19, 1999; 84(5): 611 - 619.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. J.H. Wojcikiewicz and J. A. Oberdorf
Degradation of Inositol 1,4,5-Trisphosphate Receptors during Cell Stimulation Is a Specific Process Mediated by Cysteine Protease Activity
J. Biol. Chem., July 12, 1996; 271(28): 16652 - 16655.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1993 by the American Society for Pharmacology and Experimental Therapeutics